Role of the decreased nitric oxide bioavailability in the vascular complications of diabetes mellitus

Current Pharmaceutical Biotechnology

Volumn 12, Issue 9, 2011, Pages 1354-1363

  Masha, Andi ^a   Dinatale, Stefano ^a   Allasia, Stefano ^a   Martina, Valentino ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Antioxidants; CGMP; Diabetes mellitus; Nitric oxide; Oxidation; Oxidative stress; Thiols; Vascular complications of diabetes mellitus

Indexed keywords

ACETYLCYSTEINE; ALPHA TOCOPHEROL; ANTITHROMBOCYTIC AGENT; ASCORBIC ACID; AVE 9488; CARDIOVASCULAR AGENT; CINACIGUAT; CYCLIC GMP; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FREE RADICAL; GUANYLATE CYCLASE; NITRIC OXIDE; NITRIC OXIDE DONOR; NITRIC OXIDE SYNTHASE; REACTIVE OXYGEN METABOLITE; S NITROSOGLUTATHIONE; THIOL DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; BIOAVAILABILITY; BLOOD VESSEL TONE; DIABETES MELLITUS; DIABETIC ANGIOPATHY; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; HUMAN; HYPERGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATION; PATHOPHYSIOLOGY; SYNTHESIS; TREATMENT INDICATION; TREATMENT OUTCOME;

EID: 80052240854     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/138920111798281054     Document Type: Article

References (114)

1. Furchgott, R. F.; Cherry, P. D.; Zawadzki, J. V.; Jothianandan, D. Endothelial cells as mediators of vasodilation of arteries. J. Cardiovasc. Pharmacol., 1984, 6(Suppl 2), S336-S343.
2. Collier, J.; Vallance, P. Endothelium-derived relaxing factor is an endogenous vasodilator in man. Br. J. Pharmacol., 1989, 97(3), 639-641.
3. Furchgott, R. F.; Zawadski, J. V. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature, 1980, 288, 373-376.
4. Palmer, R. M. J.; Ferrige, A. G.; Moncada, S. Nitric oxide release accounts for the biological activity of endothelial-derived relaxing factor. Nature, 1987, 327, 524-526.
5. Ignarro, L. J.; Buga, G. M.; Wood, K. S.; Byrns, R. E.; Chaudhuri, G. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc. Natl. Acad. Sci. USA, 1987, 84, 9265-9269.
6. Furchgott, R. F.; Vanhoutte, P. M. Endothelium-derived relaxing and contracting factors. FASEB J., 1989, 3(9), 2007-2018.
7. Ignarro, L. J. Endothelium-derived nitric oxide: actions and properties. FASEB J., 1989, 3(1), 31-36.
8. Cayatte, A. J.; Palacino, J. J.; Horten, K.; Cohen, R. A. Chronic inhibition of nitric oxide production accelerates neointima formation and impairs endothelial function in hypercholesterolemic rabbits. Arterioscler. Thromb., 1994, 14(5), 753-759.
9. Marletta, M. A. Nitric oxide synthase structure and mechanism. J. Biol. Chem., 1993, 268, 12231-12234.
10. Stuehr, D. J.; Griffith, O. W. Mammalian nitric oxide synthases. In: Advances in Enzymology and Related Areas of Molecular Biology, A. Meister Ed.; John Wiley and Sons: New York, NY, 1992; Vol. 65, pp. 287-346.
11. Marletta, M. A. Nitric oxide synthase: aspects concerning structure and catalysis. Cell, 1994, 78, 927-930.
12. Loscalzo, J.; Welch, G. Nitric oxide and its role in the cardiovascular system. Prog. Cardiovasc. Dis., 1995, 38, 87-104.
13. Huang, P. L.; Fishman, M. C. Genetic analysis of nitric oxide synthase isoforms: targeted mutation in mice. J. Mol. Med., 1996, 74(8), 415-421.
14. Wu, G.; Morris, S. M. Jr. Arginine metabolism: nitric oxide and beyond. Biochem. J., 1998, 336(Pt 1), 1-17.
15. Moncada, S.; Higgs, A. The L-arginine-nitric oxide pathway. N. Engl. J. Med., 1993, 329, 2002-2012.
16. Cynober, L. A. Plasma amino acid levels with a note on membrane transport: characteristics, regulation, and metabolic significance. Nutrition, 2002, 18(9), 761-766.
17. Ashina, M.; Bendtsen, L.; Jensen, R.; Olesen, J. Nitric oxideinduced headache in patients with chronic tension-type headache. J. Brain, 2000, 123, 1830-1937.
18. Vallance, P.; Collier, J.; Moncada, S. Effects of endotheliumderived nitric oxide on peripheral arteriolar tone in man. Lancet, 1989, 2(8670), 997-1000.
19. Palmer, R. M.; Rees, D. D.; Ashton, D. S.; Moncada, S. L-arginine is the physiological precursor for the formation of nitric oxide in endothelium-dependent relaxation. Biochem. Biophys. Res. Commun., 1988, 153(3), 1251-1256.
20. Rees, D. D.; Palmer, R. M.; Moncada, S. Role of endotheliumderived nitric oxide in the regulation of blood pressure. Proc. Natl. Acad. Sci. USA, 1989, 86(9), 3375-3378.
21. Vallance, P.; Chan, N. Endothelial function and nitric oxide: clinical relevance. Heart, 2001, 85(3), 342-350.
22. Boger, R. H.; Bode-Boger, S. M.; Szuba, A.; Tsao, P. S.; Chan, J. R.; Tangphao, O.; Blaschke, T. F.; Cooke, J. P. Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation, 1998, 98(18), 1842-1847.
23. Surdacki, A.; Nowicki, M.; Sandmann, J. Reduced urinary excretion of nitric oxide metabolites and increased plasma levels of asymmetrical dimethylarginine in men with essential hypertension. J. Cardiovasc. Pharmacol., 1999, 33, 652-658.
24. Boger, R. H.; Bode-Boger, S. M.; Thiele, W.; Junker, W.; Alexander, K.; Frolich, J. C. Biochemical evidence for impaired nitric oxide synthesis in patients with peripheral arterial occlusive disease. Circulation, 1997, 95, 2068-2074.
25. Boger, R. H. The emerging role of asymmetric dimethylarginine as a novel cardiovascular risk factor. Cardiovasc. Res., 2003, 59(4), 824-833.
26. Miyazaki, H.; Matsuoka, H.; Cooke, J. P.; Usui, M.; Ueda, S.; Okuda, S.; Imaizumi, T. Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis. Circulation, 1999, 99(9), 1141-1146.
27. Boger, R. H.; Sullivan, L. M.; Schwedhelm, E.; Wang, T. J.; Maas, R.; Benjamin, E. J.; Schulze, F.; Xanthakis, V.; Benndorf, R. A.; Vasan, R. S. Plasma asymmetric dimethylarginine and incidence of cardiovascular disease and death in the community. Circulation, 2009, 119(12), 1592-1600.
28. Drab, M.; Verkade, P.; Elger, M.; Kasper, M.; Lohn, M.; Lauterbach, B.; Menne, J.; Lindschau, C.; Mende, F.; Luft, F. C.; Schedl, A.; Haller, H.; Kurzchalia, T. V. Loss of caveolae, vascular dysfunction, and pulmonary defects in caveolin-1 gene-disrupted mice. Science, 2001, 293, 2449-2452.
29. Cosentino, F.; Luscher, T. F. Tetrahydrobiopterin and endothelial nitric oxide synthase activity. Cardiovasc. Res., 1999, 43, 274-278.
30. Stroes, E.; Hijmering, M.; van Zandvoort, M.; Wever, R.; Rabelink, T. J.; van Faassen, E. E. Origin of superoxide production by endothelial nitric oxide synthase. FEBS Lett., 1998, 438, 161-164.
31. Guazzi, M.; Arena, R. Endothelial dysfunction and pathophysiological correlates in atrial fibrillation. Heart, 2009, 95(2), 102-106.
32. Ando, J.; Komatsuda, T.; Kamiya, A. Cytoplasmic calcium response to fluid shear stress in cultured vascular endothelial cells. In Vitro Cell. Dev. Biol., 1988, 24(9), 871-977.
33. Helmlinger, G.; Berk, B. C.; Nerem, R.M. Calcium responses of endothelial cell monolayers subjected to pulsatile and steady laminar flow differ. Am. J. Physiol., 1995, 269(2 Pt 1), 367-375.
34. Olesen, S. P.; Clapham, D. E.; Davies, P. F. Haemodynamic shear stress activates a K+ current in vascular endothelial cells. Nature, 1988, 331(6152), 168-170.
35. Barakat, A. I.; Leaver, E. V.; Pappone, P.A.; Davies, P. F. A flowactivated chloride-selective membrane current in vascular endothelial cells. Circ. Res., 1999, 85 (9), 820-828.
36. Fleming, I.; Bauersachs, J.; Fisslthaler, B.; Busse, R. Ca2+- independent activation of the endothelial nitric oxide synthase in response to tyrosine phosphatase inhibitors and fluid shear stress. Circ. Res., 1998, 82(6), 686-695.
37. Dimmeler, S.; Fleming, I.; Fisslthaler, B.; Hermann, C.; Busse, R.; Zeiher, A. M. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature, 1999, 399(6736), 601-605.
38. Resnick, N.; Yahav, H.; Schubert, S.; Wolfovitz, E.; Shay, A. Signalling pathways in vascular endothelium activated by shear stress: relevance to atherosclerosis. Curr. Opin. Lipidol., 2000, 11(2), 167-177.
39. Arnold, W. P.; Mittal, C. K.; Katsuki, S.; Murad, F. Nitric oxide activates guanylate cyclase and increases guanosine 3':5'-cyclic monophosphate levels in various tissue preparations. Proc. Natl. Acad. Sci. USA, 1977, 74(8), 3203-3207.
40. Sayed, N.; Kim, D. D.; Fioramonti, X.; Iwahashi, T.; Duran, W. N.; Beuve, A. Nitroglycerin-induced S-nitrosylation and desensitization of soluble guanylyl cyclase contribute to nitrate tolerance. Circ. Res., 2008, 103, 606-614.
41. Ravi, K.; Brennan, L.A.; Levic, S.; Ross, P. A.; Black, S. M. Snitrosylation of endothelial nitric oxide synthase is associated with monomerization and decreased enzyme activity. Proc. Natl. Acad. Sci. USA, 2004, 101, 2619-2624.
42. Martinez-Ruiz, A.; Villanueva, L.; Gonzalez de Orduna, C.; Lopez-Ferrer, D.; Higueras, M.A.; Tarin, C.; Rodriguez-Crespo, I.; Vazquez, J.; Lamas, S. S-nitrosylation of Hsp90 promotes the inhibition of its ATPase and endothelial nitric oxide synthase regulatory activities. Proc. Natl. Acad. Sci. USA, 2005, 102, 8525-8530
43. Yasukawa, T.; Tokunaga, E.; Ota, H.; Sugita, H.; Martyn, J.A.; Kaneki, M. S-nitrosylation-dependent inactivation of Akt/protein kinase B in insulin resistance. J. Biol. Chem., 2005, 280, 7511-7518.
44. Bolotina, V.M.; Najibi, S.; Palacino, J.J.; Pagano, P.J.; Cohen, R.A. Nitric oxide directly activates calcium-dependent potassium channels in vascular smooth muscle. Nature, 1994, 368, 850-853.
45. Moro, M.A.; Russel, R.J.; Cellek, S.; Lizasoain, I.; Su, Y.; Darley-Usmar, V.M.; Radomski, M.W.; Moncada, S. CGMP mediates the vascular and platelet actions of nitric oxide: confirmation using an inhibitor of the soluble guanylyl cyclase. Proc. Natl. Acad. Sci. USA, 1996, 93, 1480-1485.
46. Versari, D.; Daghini, E.; Virdis, A.; Ghiadoni, L.; Taddei, S. Endothelial dysfunction as a target for prevention of cardiovascular disease. Diabetes Care, 2009, 32(Suppl 2), 314-321.
47. Landmesser, U.; Hornig, B.; Drexler, H. Endothelial dysfunction in hypercholesterolemia: mechanisms, pathophysiological importance, and therapeutic interventions. Semin. Thromb. Hemost., 2000, 26(5), 529-537.
48. Taddei, S.; Virdis, A.; Ghiadoni, L.; Sudano, I.; Salvetti, A. Endothelial dysfunction in hypertension. J. Cardiovasc. Pharmacol., 2001, 38 (Suppl 2), S11-S14.
49. Avogaro, A.; de Kreutzenberg, S.V.; Fadini, G. Endothelial dysfunction: causes and consequences in patients with diabetes mellitus. Diabetes Res. Clin. Pract., 2008, 82(Suppl 2), S94-S101.
50. Srivastava, K.; Narang, R.; Sreenivas, V.; Das S.; Dasn N. Association of eNOS Glu298Asp gene polymorphism with essential hypertension in Asian Indians. Clin. Chim. Acta, 2008, 387(1/2), 80-83.
51. Antoniades, C.; Tousoulis, D.; Vasiliadou, C.; Pitsavos, C.; Toutouza, M.; Tentolouris, C.; Marinou, K.; Stefanadis, C. Genetic polymorphisms G894T on the eNOS gene is associated with endothelial function and vWF levels in premature myocardial infarction survivors. Int. J. Cardiol., 2006, 107(1), 95-100.
52. de Gennaro Colonna, V.; Bianchi, M.; Pascale, V.; Ferrario, P.; Morelli, F.; Pascale, W.; Tomasoni, L.; Turiel, M. Asymmetric dimethylarginine (ADMA): an endogenous inhibitor of nitric oxide synthase and a novel cardiovascular risk molecule. Med. Sci. Monit., 2009, 15 (4), RA91-RA101.
53. Crabtree, M. J.; Smith, C. L.; Lam, G.; Goligorsky, M. S.; Gross, S. S. Ratio of 5,6,7,8-tetrahydrobiopterin to 7,8-dihydrobiopterin in endothelial cells determines glucose-elicited changes in NO vs. superoxide production by eNOS. Am. J. Physiol., 2008, 294(4), H1530-H1540.
54. Mingone, C. J.; Gupte, S. A.; Ali, N.; Oeckler, R. A., Wolin, M. S. Thiol oxidation inhibits nitric oxide-mediated pulmonary artery relaxation and guanylate cyclase stimulation. Am. J. Physiol., 2006, 290, L549-L557.
55. Beckman, J. S. Oxidative damage and tyrosine nitration from peroxynitrite. Chem. Res. Toxicol., 1996, 9(5), 836-844.
56. Stasch, J. P.; Schmidt, P. M.; Nedvetsky, P. I.; Hs, A. K.; Meurer, S.; Deile, M.; Taye, A.; Knorr, A.; Lapp, H.; Muller, H.; Turgay, Y.; Rothkegel, C.; Tersteegen, A.; Kemp-Harper, B.; Muller-Esterl, W.; Schmidt, H. H. Targeting the heme-oxidized nitric oxide receptor for selective vasodilatation of diseased blood vessels. J. Clin. Invest., 2006, 116, 2552-2561.
57. Creager, M. A.; Luscher, T. F.; Cosentino, F.; Beckman, J. A. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: Part I. Circulation, 2003, 108 (12), 1527-1532.
58. Wheatcroft, S. B.; Williams, I. L.; Shah, A. M.; Kearney, M. T. Pathophysiological implications of insulin resistance on vascular endothelial function. Diabet. Med., 2003, 20, 255-268.
59. Lusis, A. J. Atherosclerosis. Nature, 2000, 407, 233-241.
60. Williams, S. B.; Goldfine, A. B.; Timimi, F. K.; Ting, H. H.; Roddy, M. A.; Simonson, D. C.; Creager, M. A. Acute hyperglycemia attenuates endothelium-dependent vasodilation in humans in vivo. Circulation, 1998, 97, 1695-1701.
61. Brownlee, M. Biochemistry and molecular cell biology of diabetic complications. Nature, 2001, 414, 813-820.
62. Wallace, D. C. Diseases of the mitochondrial DNA. Annu. Rev. Biochem., 1992, 61, 1175-1212.
63. Trumpower, B. L. The protonmotive Q cycle. J. Biol. Chem., 1990, 265, 11409-11412.
64. Kwong, L. K.; Sohal, R. S. Substrate and site specificity of hydrogen peroxide generation in mouse mitochondria. Arch. Biochem. Biophys., 1998, 350, 118-126.
65. Korshunov, S. S.; Skulachev, V. P.; Starkov, A. A. High protonic potential actuates a mechanism of production of reactive oxygen species in mitochondria. FEBS Lett., 1997, 416, 15-18.
66. Du, X. L.; Edelstein, D.; Rossetti, L.; Fantus, I. G.; Goldberg, H.; Ziyadeh, F.; Wu, J.; Brownlee, M. Hyperglycemia-induced mitochondrial superoxide overproduction activates the hexosamine pathway and induces plasminogen activator inhibitor-1 expression by increasing Sp1 glycosylation. Proc. Natl. Acad. Sci. USA, 2000, 97, 12222-12226.
67. Rubanyi, G. M.; Vanhoutte, P. M. Superoxide anions and hyperoxia inactivate endothelium-derived relaxing factor. Am. J. Physiol., 1986, 250, H822-H827
68. Blough, N. V.; Zafiriou, O. C. Reaction of superoxide with nitric oxide to form peroxonitrite in alkaline aqueous solution. Inorg. Chem., 1985, 24, 3504-3505
69. Schulz, E.; Jansen, T.; Wenzel, P.; Daiber, A.; Munzel, T. Nitric oxide, tetrahydrobiopterin, oxidative stress, and endothelial dysfunction in hypertension. Antioxid. Redox. Signal., 2008, 10, 1115-1126
70. Mollnau, H.; Wendt, M.; Szocs, K.; Lassegue, B.; Schulz, E.; Oelze, M.; Li, H.; Bodenschatz, M.; August, M.; Kleschyov, A. L.; Tsilimingas, N.; Walter, U.; Forstermann, U.; Meinertz, T.; Griendling, K.; Munzel, T. Effects of angiotensin II infusion on the expression and function of NAD(P)H oxidase and components of nitric oxide/cGMP signaling. Circ. Res., 2002, 90, E58-E65.
71. Ignarro, L. J.; Barry, B. K.; Gruetter, D. Y.; Edwards, J. C.; Ohlstein, E. H.; Gruetter, C. A.; Baricos, W. H. Guanylate cyclase activation of nitroprusside and nitrosoguanidine is related to forma tion of S-nitrosothiol intermediates. Biochem. Biophys. Res. Commun., 1980, 94(1), 93-100.
72. Evgenov, O. V.; Pacher, P.; Schmidt, P. M.; Hasko, G.; Schmidt, H. H.; Stasch, J. P. NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential. Nat. Rev. Drug. Discov., 2006, 5, 755-768.
73. Drexler, H. Endothelial dysfunction: clinical implications. Prog. Cardiovasc. Dis., 1997, 39 (4), 287-324.
74. Cohen, R. A. The role of nitric oxide and other endotheliumderived vasoactive substances in vascular disease. Prog. Cardiovasc. Dis., 1995, 38(2), 105-128.
75. Tesfamariam, B.; Brown, M. L.; Cohen, R. A. Elevated glucose impairs endothelium-dependent relaxation by activating protein kinase C. J. Clin. Invest., 1991, 87(5), 1643-1648.
76. de Vriese, A. S.; Verbeuren, T. J.; Van de Voorde, J.; Lameire, N. H.; Vanhoutte, P. M. Endothelial dysfunction in diabetes. Br. J. Pharmacol., 2000, 130(5), 963-974.
77. Kobayashi, T.; Kamata, K. Relationship among cholesterol, superoxide anion and endothelium-dependent relaxation in diabetic rats. Eur. J. Pharmacol., 1999, 367(2/3), 213-222.
78. Diederich, D.; Skopec, J.; Diederich, A.; Dai, F. X. Endothelial dysfunction in mesenteric resistance arteries of diabetic rats: role of free radicals. Am. J. Physiol., 1994, 266(3 Pt 2), H1153-H1161.
79. Rodriguez-Manas, L.; Angulo, J.; Peiro, C.; Llergo, J.L.; Sanchez-Ferrer, A.; Lopez-Doriga, P.; Sanchez-Ferrer, C.F. Endothelial dysfunction and metabolic control in streptozotocin-induced diabetic rats. Br. J. Pharmacol., 1998, 123(8), 1495-1502.
80. Pieper, G.M. Enhanced, unaltered and impaired nitric oxidemediated endothelium-dependent relaxation in experimental diabetes mellitus: importance of disease duration. Diabetologia, 1999, 42(2), 204-213.
81. Cosentino, F.; Hishikawa, K.; Katusic, Z.S.; Luscher, T.F. High glucose increases nitric oxide synthase expression and superoxide anion generation in human aortic endothelial cells. Circulation, 1997, 96(1), 25-28.
82. Rosen, P.; Ballhausen, T.; Stockklauser, K. Impairment of endothelium dependent relaxation in the diabetic rat heart: mechanisms and implications. Diabetes Res. Clin. Pract., 1996, 31 (Suppl.), S143-S155.
83. de Vriese, A.S.; Van de Voorde, J.; Blom, H.J.; Vanhoutte, P.M.; Verbeke, M.; Lameire, N.H. The impaired renal vasodilator response attributed to endothelium-derived hyperpolarizing factor in streptozotocin-induced diabetic rats is restored by 5-methyltetrahydrofolate. Diabetologia, 2000, 43(9), 1116-1125.
84. Saenz de Tejada, I.; Goldstein, I.; Azadzoi, K.; Krane, R. J.; Cohen, R. A. Impaired neurogenic and endothelium-mediated relaxation of penile smooth muscle from diabetic men with impotence. N. Engl. J. Med., 1989, 320, 1025-1030.
85. Williamson, J. R.; Chang, K.; Frangos, M.; Hasan, K. S.; Ido, Y.; Kawamura, T.; Nyengaard, J. R.; van den Enden, M.; Kilo, C.; Tilton, R.G. Hyperglycemic pseudohypoxia and diabetic complications. Diabetes, 1993, 42(6), 801-813.
86. Vervoort, G.; Wetzels, J. F.; Lutterman, J. A.; van Doorn, L. G.; Berden, J. H.; Smits, P. Elevated skeletal muscle blood flow in noncomplicated type 1 diabetes mellitus: role of nitric oxide and sympathetic tone. Hypertension, 1999, 34(5), 1080-1085.
87. Pieper, G. M.; Gross, G. J. Oxygen free radicals abolish endothelium- dependent relaxation in diabetic rat aorta. Am. J. Physiol., 1988, 255(4 Pt 2), H825-H833.
88. Nitenberg, A.; Valensi, P.; Sachs, R.; Dali, M.; Aptecar, E.; Attali, J. R. Impairment of coronary vascular reserve and ACh-induced coronary vasodilation in diabetic patients with angiographically normal coronary arteries and normal left ventricular systolic function. Diabetes, 1993, 42(7), 1017-1025.
89. Johnstone, M. T.; Creager, S. J.; Scales, K. M.; Cusco, J.A.; Lee, B. K.; Creager, M. A. Impaired endothelium-dependent vasodilation in patients with insulin-dependent diabetes mellitus. Circulation, 1993, 88(6), 2510-2516.
90. Elliott, T. G.; Cockcroft, J. R.; Groop, P. H.; Viberti, G. C.; Ritter, J.M. Inhibition of nitric oxide synthesis in forearm vasculature of insulin-dependent diabetic patients: blunted vasoconstriction in patients with microalbuminuria. Clin. Sci. (Lond.)., 1993, 85(6), 687-693.
91. Zenere, B. M.; Arcaro, G.; Saggiani, F.; Rossi, L.; Muggeo, M.; Lechi, A. Noninvasive detection of functional alterations of the arterial wall in IDDM patients with and without microalbuminuria. Diabetes Care, 1995, 18(7), 975-982.
92. Tomaskova, Z.; Cacanyiova, S.; Benco, A.; Kristek, F.; Dugovicova, L.; Hrbac, J.; Ondrias, K. Lipids modulate H(2)S/HS(-) induced NO release from S-nitrosoglutathione. Biophys. Res. Commun., 2009, 390(4), 1241-1244.
93. Sakamoto, S.; Minami, K.; Niwa, Y.; Ohnaka, M.; Nakaya, Y.; Mizuno, A.; Kuwajima, M.; Shima, K. Effect of exercise training and food restriction on endothelium-dependent relaxation in the Otsuka Long-Evans Tokushima Fatty rat, a model of spontaneous NIDDM. Diabetes, 1998, 47(1), 82-86.
94. Cooke, J.P. Therapeutic interventions in endothelial dysfunction: endothelium as a target organ. Clin. Cardiol., 1997, 20(11 Suppl 2), 45-51.
95. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med., 1993, 329(14), 977-986.
96. Anderson, T. J.; Meredith, I. T.; Yeung, A. C.; Frei, B.; Selwyn, A. P.; Ganz, P. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N. Engl. J. Med., 1995, 332(8), 488-493.
97. Wiemer, G.; Linz, W.; Hatrik, S.; Scholkens, B. A.; Malinski, T. Angiotensin-converting enzyme inhibition alters nitric oxide and superoxide release in normotensive and hypertensive rats. Hypertension, 1997, 30(5), 1183-1190.
98. Hayoz, D.; Ziegler, T.; Brunner, H. R.; Ruiz, J. Diabetes mellitus and vascular lesions. Metabolism, 1998, 47(12 Suppl 1), 16-19.
99. Artaud-Wild, S. M.; Connor, S.L.; Sexton, G.; Connor, W. E. Differences in coronary mortality can be explained by differences in cholesterol and saturated fat intakes in 40 countries but not in France and Finland. A paradox. Circulation, 1993, 88(6), 2771-2779.
100. Ceriello, A.; Quagliaro, L.; Catone, B.; Pascon, R.; Piazzola, M.; Bais, B.; Marra, G.; Tonutti, L.; Taboga, C.; Motz, E. Role of hyperglycemia in nitrotyrosine postprandial generation. Diabetes Care, 2002, 25(8), 1439-1443.
101. Ceriello, A.; Bortolotti, N.; Crescentini, A.; Motz, E.; Lizzio, S.; Russo, A.; Ezsol, Z.; Tonutti, L.; Taboga, C. Antioxidant defences are reduced during the oral glucose tolerance test in normal and non-insulin-dependent diabetic subjects. Eur. J. Clin. Invest., 1998, 28(4), 329-333.
102. Ceriello, A.; Bortolotti, N.; Falleti, E.; Taboga, C.; Tonutti, L.; Crescentini, A.; Motz, E.; Lizzio, S.; Russo, A.; Bartoli, E. Total radical-trapping antioxidant parameter in NIDDM patients. Diabetes Care, 1997, 20(2), 194-197.
103. Aguirre, F.; Martin, I.; Grinspon, D.; Ruiz, M.; Hager, A.; de Paoli, T.; Ihlo, J.; Farach, H.A.; Poole, C.P. Jr. Oxidative damage, plasma antioxidant capacity, and glucemic control in elderly NIDDM patients. Free. Radic. Biol. Med., 1998, 24(4), 580-585.
104. Lonn, E.; Yusuf, S.; Hoogwerf, B.; Pogue, J.; Yi, Q.; Zinman, B.; Bosch, J.; Dagenais, G.; Mann, J. F.; Gerstein, H. C.; HOPE Study; MICRO-HOPE Study. Effects of vitamin E on cardiovascular and microvascular outcomes in high-risk patients with diabetes: results of the HOPE study and MICRO-HOPE substudy. Diabetes Care, 2002, 25(11), 1919-1927.
105. Ignarro, L. J.; Edwards, J. C.; Gruetter, D. Y.; Barry, B. K.; Gruetter, C. A. Possible involvement of S-nitrosothiols in the activation of guanylate cyclase by nitroso compounds. FEBS Lett., 1980, 110(2), 275-278.
106. Pieper, G. M.; Siebeneich, W. Oral administration of the antioxidant, N-acetylcysteine, abrogates diabetes-induced endothelial dysfunction. J. Cardiovasc. Pharmacol., 1998, 32(1), 101-105.
107. Pieper, G. M. Acute amelioration of diabetic endothelial dysfunction with a derivative of the nitric oxide synthase cofactor, tetrahydrobiopterin. J. Cardiovasc. Pharmacol., 1997, 29(1), 8-15.
108. Martina, V.; Bruno, G. A.; Zumpano, E.; Origlia, C.; Quaranta, L.; Pescarmona, G. P. Administration of glutathione in patients with type 2 diabetes mellitus increases the platelet constitutive nitric oxide synthase activity and reduces PAI-1. J. Endocrinol. Invest., 2001, 24 (1), 37-41.
109. Masha, A.; Brocato, L.; Dinatale, S.; Mascia, C.; Biasi, F.; Martina, V. N-acetylcysteine is able to reduce the oxidation status and the endothelial activation after a high-glucose content meal in patients with Type 2 diabetes mellitus. J. Endocrinol. Invest., 2009, 32(4), 352-356.
110. Martina, V.; Masha, A.; Gigliardi, V. R.; Brocato, L.; Manzato, E.; Berchio, A.; Massarenti, P.; Settanni, F.; Della Casa, L.; Bergamini, S.; Iannone, A. Long-term N-acetylcysteine and L-arginine administration reduces endothelial activation and systolic blood pressure in hypertensive patients with type 2 diabetes. Diabetes Care, 2008, 31(5), 940-944.
111. Hofmann, H.; Schmidt, H. H. Thiol dependence of nitric oxide synthase. Biochemistry, 1995, 34, 13443-13452.
112. Vita, J. A.; Frei, B.; Holbrook, M.; Gokce, N.; Leaf, C.; Keaney, J. F. L-2-oxothiazolidine-4-carboxylic acid reverses endothelial dysfunction in patients with coronary artery disease. J. Clin. Invest., 1998, 101, 1408-1414.
113. Stasch, J. P.; Becker, E. M.; Alonso-Alija, C.; Apeler, H.; Dembowsky, K.; Feurer, A.; Gerzer, R.; Minuth, T.; Perzborn, E.; Pleiss, U.; Schroder, H.; Schroeder, W.; Stahl, E.; Steinke, W.; Straub, A.; Schramm, M. NO-independent regulatory site on soluble guanylate cyclase. Nature, 2001, 410, 212-215.
114. Guzik, T. J.; Mussa, S.; Gastaldi, D.; Sadowski, J.; Ratnatunga, C.; Pillai, R.; Channon, K. M. Mechanisms of increased vascular superoxide production in human diabetes mellitus: role of NAD(P)H oxidase and endothelial nitric oxide synthase. Circulation, 2002, 105, 1656-1662.